Edwards Lifesciences (NYSE:EW) Price Target Raised to $90.00 at Barclays

Edwards Lifesciences (NYSE:EW) had its target price increased by investment analysts at Barclays from $88.00 to $90.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target points to a potential upside of 18.83% from the stock’s current price.

EW has been the topic of several other reports. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup lifted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. The Goldman Sachs Group increased their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday. Finally, Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.08 on Thursday, reaching $75.74. The stock had a trading volume of 1,220,042 shares, compared to its average volume of 4,456,875. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $44.67 billion, a P/E ratio of 10.93, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The firm has a fifty day moving average of $72.51 and a two-hundred day moving average of $69.36. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, equities research analysts anticipate that Edwards Lifesciences will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently modified their holdings of the business. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth about $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $30,000. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. Finally, Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $32,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.